DND Pharm

D&D Pharmatech is a clinical-stage biopharmaceutical company based in South Korea that develops innovative therapies for metabolic, neurodegenerative, and fibrotic diseases. The company utilizes its proprietary ORALINK platform to create orally bioavailable peptide drugs, notably targeting the GLP-1 receptor pathway for obesity and MASH. Its lead candidate, DD01, is a long-acting GLP-1/glucagon dual agonist currently in Phase 2 development for MASH, while NLY01 is a GLP-1 receptor agonist being evaluated for Parkinson's and Alzheimer's diseases. D&D Pharmatech operates through a network of US-based subsidiaries, including Neuraly and Theraly, and recently established a significant partnership with Metsera to advance its oral metabolic pipeline. The company successfully listed on the KOSDAQ exchange in May 2024.